Evotec Earns Boehringer Milestone

Evotec AG has reached a milestone triggering a $2.6 million payment in its research alliance with Boehringer Ingelheim. The milestone was for the transition of an oncology program into lead optimization.

Dr. Mario Polywka, chief operating officer of Evotec, said, “This is the 11th milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target. We continue to enjoy a very rich scientific partnership with Boehringer Ingelheim and look forward to continued success through our joint project teams in the coming years.”

In 2004, the two companies entered into a multi-year, multi-target drug discovery alliance to jointly identify and develop preclinical candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.